Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Healthcare
Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Knight Therapeutics Inc > Listened to the Stifel-GMP call again ...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(3)
•••
Comment by porksnifferon Dec 10, 2021 12:24pm
101 Views
Post# 34219027

RE:RE:RE:RE:Listened to the Stifel-GMP call again ...

RE:RE:RE:RE:Listened to the Stifel-GMP call again ...
MrMugsy wrote:
Candyswanwick wrote:

PorkSniffer.. I'm just lost as to why you still own GUD shares based on how you feel about the company. Blows my mind. Do you have anything positive to say about GUD? If not why are you still holding on to shares? 



Candy - I think Porky did a self-proclaimed exit and he was one who purchased at $10 - along with the other two full-time haters.  

He’ll tell you he’s glad he left ... that Meir was correct???? and that Goodman is taking this company private????

If nothing else ... it was funny until it got sad.  He can’t even admit that I warned (since 2014) that this is a long game and accumulation is the only way I can play this successfully.  Porky kept saying I was wrong but I’m not sure where I led him astray.

hahaha !  

And these are the days of our lives.




Always happy to see you get smashed in Antibe. You are also getting crushed here. Kindly tell the board how much money you have lost pumping these two T U R D S? "Love it." 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities